Managing Cancer Treatment in Patients with Renal Dysfunction: The Role of Chemotherapy


Дәйексөз келтіру

Толық мәтін

Аннотация

Malignancy is characterized by damage to several vital organs, and utilizing chemotherapy as a treatment option can have toxic effects on healthy body tissues. Kidney function is commonly compromised by cancer and chemotherapy. These effects can be pre-renal, intrarenal, or postrenal. Tumor lysis syndrome and electrolyte disturbances are also common in this group of patients. Etiologies of this dysfunction are poorly understood; therefore, careful monitoring and management of renal function are required in such cases. This narrative review aimed to highlight some of the common renal abnormalities among patients receiving cancer and chemotherapy.

Негізгі сөздер

Авторлар туралы

Ziba Aghsaeifard

Urology Research Center, Tehran University of Medical Sciences

Email: info@benthamscience.net

Reza Alizadeh

Department of Anesthesiology and Intensive Care, AJA University of Medical Sciences,

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Aghsaeifard, Z.; Ghafarzadeh, M.; Alizadeh, R. Pregnancy and sex hormone changes after kidney transplant. Clin. Invest. Ginecol. Obstet., 2023, 50(1), 100812. doi: 10.1016/j.gine.2022.100812
  2. Canet, E.; Zafrani, L.; Lambert, J.; Thieblemont, C.; Galicier, L.; Schnell, D.; Raffoux, E.; Lengline, E.; Chevret, S.; Darmon, M.; Azoulay, E. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One, 2013, 8(2), e55870. doi: 10.1371/journal.pone.0055870 PMID: 23457485
  3. Alizadeh, R.; Aghsaeifard, Z. Two-way road of kidney and hypercalcemia: A narrative review. Cardiovasc. Hematol. Disord. Drug Targets, 2022, 22(4), 200-206. doi: 10.2174/1871529X23666221205143041 PMID: 36475333
  4. Rosner, M.H.; Perazella, M.A. Acute kidney injury in patients with cancer. N. Engl. J. Med., 2017, 376(18), 1770-1781.https://www.nejm.org/doi/full/10.1056/NEJMra1613984 doi: 10.1056/NEJMra1613984 PMID: 28467867
  5. Aghsaeifard, Z.; Alizadeh, R.; Bagheri, N. Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch. Physiol. Biochem., 2022, 128(3), 703-707. doi: 10.1080/13813455.2020.1720742 PMID: 31994917
  6. Miao, J.; Sise, M.E.; Herrmann, S.M. Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. Front. Neurol., 2022, 2, 1017921. doi: 10.3389/fneph.2022.1017921
  7. Alizadeh, R.; Aghsaeifard, Z. Clinical post-transplant lymphoproliferative disorders. Cardiovasc. Hematol. Disord. Drug Targets, 2022, 22(2), 96-103. doi: 10.2174/1871529X22666220804155810
  8. Santos, M.L.C.; Brito, B.B.; Silva, F.A.F.; Botelho, A.C.S.; Melo, F.F. Nephrotoxicity in cancer treatment: An overview. World J. Clin. Oncol., 2020, 11(4), 190-204. doi: 10.5306/wjco.v11.i4.190 PMID: 32355641
  9. Małyszko, J.; Kozlowski, L.; Kozłowska, K.; Małyszko, M.; Małyszko, J. Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget, 2017, 8(39), 66601-66619. doi: 10.18632/oncotarget.18094 PMID: 29029541
  10. Amarapurkar, P.; Bou-Slaiman, S.; Madrid, B.; Ladino, M. Paraneoplastic glomerular disease: The struggle is real. J. Onco-Nephrol., 2019, 3(1), 31-38. doi: 10.1177/2399369319828732
  11. Lefaucheur, C.; Stengel, B.; Nochy, D.; Martel, P.; Hill, G.S.; Jacquot, C.; Rossert, J. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int., 2006, 70(8), 1510-1517. doi: 10.1038/sj.ki.5001790 PMID: 16941021
  12. Jhaveri, K.D.; Shah, H.H.; Calderon, K.; Campenot, E.S.; Radhakrishnan, J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int., 2013, 84(1), 34-44. doi: 10.1038/ki.2012.484 PMID: 23364518
  13. Aghsaeifard, Z.; Alizadeh, R. Drug-induced interstitial nephritis as a result of sodium valproate and triamterene. Urol. Case Rep., 2020, 33, 101329. doi: 10.1016/j.eucr.2020.101329 PMID: 33102031
  14. Beck, L.H., Jr PLA2R and THSD7A: Disparate paths to the same disease? J. Am. Soc. Nephrol., 2017, 28(9), 2579-2589. doi: 10.1681/ASN.2017020178 PMID: 28674044
  15. Küppers, R.; Schwering, I.; Bräuninger, A.; Rajewsky, K.; Hansmann, M.L. Biology of Hodgkin's lymphoma. Ann. Oncol., 2002, 13(Suppl. 1), 11-18. doi: 10.1093/annonc/13.S1.11 PMID: 12078890
  16. Cambier, Jean-François; Ronco, Pierre Onco-nephrology: Glomerular diseases with cancer. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1701-1712. doi: 10.2215/CJN.03770412
  17. Ronco, P.; Plaisier, E. Immunoglobulin light (heavy)-chain deposition disease: From molecular medicine to pathophysiology-driven therapy. Clin. J. Amer. Soc. Nephrol., 2006, 1(6), 1342-1350. doi: 10.2215/CJN.01730506
  18. Gnemmi, V.; Leleu, X.; Provot, F.; Moulonguet, F.; Buob, D. Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia. Am. J. Kidney Dis., 2012, 60(3), 487-491. doi: 10.1053/j.ajkd.2012.01.030 PMID: 22721930
  19. Toriu, N.; Sawa, N.; Imafuku, A.; Hasegawa, E.; Sekine, A.; Mizuno, H.; Yamanouchi, M.; Hiramatsu, R.; Hayami, N.; Hoshino, J.; Kawada, M.; Suwabe, T.; Ohashi, K.; Fujii, T.; Ubara, Y. Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. CEN Case Rep., 2020, 9(4), 347-353. doi: 10.1007/s13730-020-00485-7 PMID: 32378178
  20. Heo, M.H.; Kim, H.K.; Lee, H.; Ahn, M.J. Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: A case report. J. Thorac. Oncol., 2017, 12(8), e103-e105. doi: 10.1016/j.jtho.2017.03.011 PMID: 28342816
  21. Wu, S.; Dahut, W.L.; Gulley, J.L. The use of bisphosphonates in cancer patients. Acta Oncol., 2007, 46(5), 581-591. doi: 10.1080/02841860701233435 PMID: 17562434
  22. Jia, N.; Cormack, F.C.; Xie, B.; Shiue, Z.; Najafian, B.; Gralow, J.R. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer, 2015, 15(1), 535. doi: 10.1186/s12885-015-1536-y PMID: 26197890
  23. Miller, P.D. The kidney and bisphosphonates. Bone, 2011, 49(1), 77-81. doi: 10.1016/j.bone.2010.12.024 PMID: 21232648
  24. Oberic, L.; Buffet, M.; Schwarzinger, M.; Veyradier, A.; Clabault, K.; Malot, S.; Schleinitz, N.; Valla, D.; Galicier, L.; Bengrine-Lefèvre, L.; Gorin, N.C.; Coppo, P. Cancer awareness in atypical thrombotic microangiopathies. Oncologist, 2009, 14(8), 769-779. doi: 10.1634/theoncologist.2009-0067 PMID: 19684072
  25. Mielczarek, Ł. Brodziak, A.; Sobczuk, P.; Kawecki, M.; Cudnoch-Jędrzejewska, A.; Czarnecka, A.M. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother. Pharmacol., 2021, 87(6), 723-742. doi: 10.1007/s00280-021-04260-y PMID: 33768301
  26. Al-Nouri, Z.L.; Reese, J.A.; Terrell, D.R.; Vesely, S.K.; George, J.N. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125(4), 616-618. doi: 10.1182/blood-2014-11-611335 PMID: 25414441
  27. Lien, Y.H.H.; Lai, L.W. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat. Rev. Nephrol., 2011, 7(2), 85-95. doi: 10.1038/nrneph.2010.171 PMID: 21151207
  28. Hausberg, M.; Felten, H.; Pfeffer, S. Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer. Case Rep. Oncol., 2019, 12(1), 1-6. doi: 10.1159/000495031 PMID: 30792638
  29. Kapiteijn, E.; Brand, A.; Kroep, J.; Gelderblom, H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol., 2007, 18(10), 1745-1747. doi: 10.1093/annonc/mdm454 PMID: 17890216
  30. Morton, J.M.; George, J.N. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J. Oncol. Pract., 2016, 12(6), 523-530.https://ascopubs.org/doi/full/10.1200/jop.2016.012096 doi: 10.1200/JOP.2016.012096 PMID: 27288467
  31. Winters, J.L. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology (Am. Soc. Hematol. Educ. Program), 2017, 2017(1), 632-638. doi: 10.1182/asheducation-2017.1.632 PMID: 29222314
  32. Lam, A.Q.; Humphreys, B.D. Onco-Nephrology. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1692-1700. doi: 10.2215/CJN.03140312 PMID: 22879433
  33. Campbell, G.A.; Hu, D.; Okusa, M.D. Acute kidney injury in the cancer patient. Adv. Chronic Kidney Dis., 2014, 21(1), 64-71. doi: 10.1053/j.ackd.2013.08.002 PMID: 24359988
  34. Okada, H.; Kikuta, T.; Kobayashi, T.; Inoue, T.; Kanno, Y. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Amer. Soc. Nephrol., 2005, 16(1), 133-143. doi: 10.1681/ASN.2004040339
  35. Aghsaeifard, Z.; Latifi, M.; Bagherpour, F.; Rahbar, M.; Rahimzadeh, H.; Namdari, F.; Dialameh, H.; Taheri Mahmoudi, M.; Dehghani, S. Choriocarcinoma transmitted with the transplant: Case study. SAGE Open Med. Case Rep., 2022, 10, 2050313X2210875. doi: 10.1177/2050313X221087567 PMID: 35449531
  36. Vaglio, A.; Maritati, F. Idiopathic retroperitoneal fibrosis. J. Am. Soc. Nephrol., 2016, 27(7), 1880-1889. doi: 10.1681/ASN.2015101110 PMID: 26860343
  37. Surcel, C.; Mirvald, C.; Pavelescu, C.; Gingu, C.; Carmen, S.; Emre, H.; Ioanel, S. Management of idiopathic retroperitoneal fibrosis from the urologist's perspective. Ther. Adv. Urol., 2015, 7(2), 85-99. doi: 10.1177/1756287214565637
  38. Ingles Garces, A.H.; Ang, J.E.; Ameratunga, M.; Chénard-Poirier, M.; Dolling, D.; Diamantis, N.; Seeramreddi, S.; Sundar, R.; de Bono, J.; Lopez, J.; Banerji, U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Eur. J. Cancer, 2018, 104(104), 32-38. doi: 10.1016/j.ejca.2018.08.019 PMID: 30316017
  39. Gupta, R.; Matthew, N.J. Hypercalcemia due to vitamin D-secreting hodgkin's lymphoma exacerbated by oral calcium supplementation. Endocrine Practice, 12(2), 227-229. doi: 10.4158/EP.12.2.227
  40. Berardi, R.; Rinaldi, S.; Caramanti, M.; Grohè, C.; Santoni, M.; Morgese, F.; Torniai, M.; Savini, A.; Fiordoliva, I.; Cascinu, S. Hyponatremia in cancer patients: Time for a new approach. Crit. Rev. Oncol. Hematol., 2016, 102, 15-25. doi: 10.1016/j.critrevonc.2016.03.010 PMID: 27066939
  41. Onitilo, A.A.; Kio, E.; Doi, S.A.R. Tumor-related hyponatremia. Clin. Med. Res., 2007, 5(4), 228-237. doi: 10.3121/cmr.2007.762 PMID: 18086907
  42. Mentrasti, G.; Scortichini, L.; Torniai, M.; Giampieri, R.; Morgese, F.; Rinaldi, S.; Berardi, R. Syndrome of inappropriate antidiuretic hormone secretion (SIADH): Optimal management. Ther. Clin. Risk Manag., 2020, 16, 663-672. doi: 10.2147/TCRM.S206066 PMID: 32801723
  43. Verzicco, I.; Regolisti, G.; Quaini, F.; Bocchi, P.; Brusasco, I.; Ferrari, M.; Passeri, G.; Cannone, V.; Coghi, P.; Fiaccadori, E.; Vignali, A.; Volpi, R.; Cabassi, A. Electrolyte disorders induced by antineoplastic drugs. Front. Oncol., 2020, 10, 779. doi: 10.3389/fonc.2020.00779 PMID: 32509580
  44. Shirali, A. Electrolyte and acid-base disorders in malignancy.Onco-nephrology curriculum; American society of nephrology: Washington, DC, USA, 2016.
  45. Rosner, M.H.; Perazella, M.A. Acute kidney injury in the patient with cancer. Kidney Res. Clin. Pract., 2019, 38(3), 295-308. doi: 10.23876/j.krcp.19.042 PMID: 31284363
  46. Bowman, B.T. Electrolyte disorders associated with cancer. Journal of Onco-Nephrology, 2017, 1(1), 30-35. doi: 10.5301/jo-n.5000004
  47. Chaudhary, D.P.; Sharma, R.; Bansal, D.D. Implications of magnesium deficiency in type 2 diabetes: a review. Biol. Trace Elem. Res., 2010, 134(2), 119-129. doi: 10.1007/s12011-009-8465-z PMID: 19629403
  48. Lam, M.; Adelstein, D.J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am. J. Kidney Dis., 1986, 8(3), 164-169. doi: 10.1016/S0272-6386(86)80020-8 PMID: 3752072
  49. Rude, R.K. Magnesium deficiency: a cause of heterogeneous disease in humans. J. Bone Miner. Res., 1998, 13(4), 749-758. doi: 10.1359/jbmr.1998.13.4.749 PMID: 9556074
  50. Dreizen, S.; McCredie, K.B.; Keating, M.J.; Andersson, B.S. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad. Med., 1990, 87(1), 163-170, 170. doi: 10.1080/00325481.1990.11704531 PMID: 2296564
  51. Gupta, D.; Vashi, P.G.; Trukova, K.; Lis, C.G.; Lammersfeld, C.A. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp. Ther. Med., 2011, 2(2), 181-193. doi: 10.3892/etm.2011.205 PMID: 22977487
  52. Pullar, J.; Carr, A.; Vissers, M. The roles of vitamin C in skin health. Nutrients, 2017, 9(8), 866. doi: 10.3390/nu9080866 PMID: 28805671
  53. Darmon, M.; Vincent, F.; Camous, L.; Canet, E.; Bonmati, C.; Braun, T.; Caillot, D.; Cornillon, J.; Dimicoli, S.; Etienne, A.; Galicier, L.; Garnier, A.; Girault, S.; Hunault-Berger, M.; Marolleau, J.P.; Moreau, P.; Raffoux, E.; Recher, C.; Thiebaud, A.; Thieblemont, C.; Azoulay, E. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br. J. Haematol., 2013, 162(4), 489-497. doi: 10.1111/bjh.12415 PMID: 23772757
  54. Sherwood, G.B.; Paschal, R.D.; Adamski, J. Rasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. Clin. Case Rep., 2016, 4(4), 315-319. doi: 10.1002/ccr3.495 PMID: 27099716
  55. Mirrakhimov, A.E.; Ali, A.M.; Khan, M.; Barbaryan, A. Tumor lysis syndrome in solid tumors: An up to date review of the literature. Rare Tumors, 2014, 6(2), 68-76. doi: 10.4081/rt.2014.5389 PMID: 25002953
  56. Abu-Alfa, A.K.; Younes, A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am. J. Kidney Dis., 2010, 55(5)(Suppl. 3), S1-S13. doi: 10.1053/j.ajkd.2009.10.056 PMID: 20420966
  57. Reed, D.R.; Pierce, E.J.; Sen, J.M.; Keng, M.K. A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. Cancer Manag. Res., 2019, 11, 8065-8072. doi: 10.2147/CMAR.S190084 PMID: 31507329
  58. Chen, C.; Lü, J.M.; Yao, Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: An overview. Med. Sci. Monit., 2016, 22, 2501-2512. doi: 10.12659/MSM.899852 PMID: 27423335
  59. Pession, A.; Melchionda, F.; Castellini, C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics, 2008, 2(1), 129-141. PMID: 19707436
  60. Chao, J.; Terkeltaub, R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep., 2009, 11(2), 135-140. doi: 10.1007/s11926-009-0019-z PMID: 19296886
  61. Bessmertny, O.; Robitaille, L.; Cairo, M. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr. Pharm. Des., 2005, 11(32), 4177-4185. doi: 10.2174/138161205774913291 PMID: 16375739
  62. Cairo, M.S.; Bishop, M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol., 2004, 127(1), 3-11. doi: 10.1111/j.1365-2141.2004.05094.x PMID: 15384972
  63. Vadhan-Raj, S.; Fayad, L.E.; Fanale, M.A.; Pro, B.; Rodriguez, A.; Hagemeister, F.B.; Bueso-Ramos, C.E.; Zhou, X.; McLaughlin, P.W.; Fowler, N.; Shah, J.; Orlowski, R.Z.; Samaniego, F.; Wang, M.; Cortes, J.E.; Younes, A.; Kwak, L.W.; Sarlis, N.J.; Romaguera, J.E. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann. Oncol., 2012, 23(6), 1640-1645. doi: 10.1093/annonc/mdr490 PMID: 22015451
  64. Nakamura, M.; Oda, S.; Sadahiro, T.; Hirayama, Y.; Tateishi, Y.; Abe, R.; Hirasawa, H. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus. Apheresis Sci., 2009, 40(1), 41-47. doi: 10.1016/j.transci.2008.11.004 PMID: 19109071
  65. Lin, C.J.; Chen, H.H.; Hsieh, R.K.; Chen, Y.C.; Wu, C.J. Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. Med. Oncol., 2009, 26(1), 93-95. doi: 10.1007/s12032-008-9064-0 PMID: 18770053
  66. Humphreys; Benjamin, D. Soiffer, R.J.; Magee, C.C. Renal failure associated with cancer and its treatment: An update. J. Amer. Soc. Nephrol., 2005, 16(1), 151-161. doi: 10.1681/ASN.2004100843
  67. Wilson, F.P.; Berns, J.S. Tumor lysis syndrome: new challenges and recent advances. Adv. Chronic Kidney Dis., 2014, 21(1), 18-26. doi: 10.1053/j.ackd.2013.07.001 PMID: 24359983
  68. Małyszko, J.; Kozłowska, K.; Kozłowski, L.; Małyszko, J. Nephrotoxicity of anticancer treatment. Nephrol. Dial. Transplant., 2016, 32(6), gfw338. doi: 10.1093/ndt/gfw338 PMID: 28339935
  69. Jagieła, J.; Bartnicki, P.; Rysz, J. Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int. J. Mol. Sci., 2021, 22(9), 4618. doi: 10.3390/ijms22094618 PMID: 33924827
  70. Gupta, S.; Gudsoorkar, P.; Jhaveri, K.D. Acute kidney injury in critically Ill patients with cancer. Clin. J. Am. Soc. Nephrol., 2022, 17(9), 1385-1398. doi: 10.2215/CJN.15681221
  71. Chiruvella, V.; Annamaraju, P.; Guddati, A.K. Management of nephrotoxicity of chemotherapy and targeted agents. Am. J. Cancer Res., 2020, 10(12), 4151-4164. PMID: 33414992
  72. Lotfi, R.; Tehrani, F.R.; Dovom, M.R.; Torkestani, F.; Abedini, M.; Sajedinejad, S. Development of strategies to reduce cesarean delivery rates in iran 2012-2014: a mixed methods study. Int. J. Prev. Med., 2014, 5(12), 1552-1566. PMID: 25709791
  73. Li, H.; Xu, J.; Bai, Y.; Zhang, S.; Cheng, M.; Jin, J. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: A systematic review and meta-analysis. Invest. New Drugs, 2021, 39(3), 860-870. doi: 10.1007/s10637-020-01039-5 PMID: 33409896

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2023